Top stories in cardiology: Clinical review of COVID-19 and CVD, new guidance for electrophysiologists
Experts recently provided a summary of the evolving molecular and clinical data on COVID-19, with a focus on how it impacts patients with cardiovascular disease. It was the top story in cardiology last week.
Another top story was about new guidance from cardiology societies that address COVID-19 concerns regarding electrophysiologists and stroke centers.
Read these and more top stories in cardiology below:
Clinical review of COVID-19 and CVD: What the cardiovascular practitioner needs to know
The novel coronavirus disease, or COVID-19, is now a global pandemic. Clinicians, scientists and public health officials around the world are racing to define the molecular pathway and clinical presentation of the virus, identify risk factors for infection and poor clinical outcomes, and develop effective treatments and preventive interventions. Read more.
Societies advise on COVID-19 concerns for electrophysiologists, stroke centers
In light of the COVID-19 pandemic, cardiology societies have issued new guidance on concerns related to the virus relevant to electrophysiologists and stroke centers. Read more.
VICTORIA: Vericiguat reduces events in high-risk heart failure
Vericiguat, a novel oral soluble guanylate cyclase stimulator, reduced the incidence of heart failure hospitalization or cardiovascular death compared with placebo in patients with high-risk heart failure, according to data from the VICTORIA trial presented at the American College of Cardiology Scientific Session. Read more.
CV benefits, weight loss similar among most popular diets at 6 months
Most macronutrient diets led to substantial improvements in cardiovascular risk factors and modest weight loss over months, according to a systematic review and network meta-analysis published in The BMJ. Read more.
‘Genetics is not destiny’: Lifetime CVD risk prediction varies by exposure to elevated LDL, BP
Regardless of polygenic risk score for coronary artery disease, lifetime risk for CVD varies greatly depending on exposure to elevated LDL and systolic BP, according to research presented at the virtual American College of Cardiology Scientific Session. Read more.